CNXC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Concentrix Corp (CNXC) is not an ideal buy for a beginner, long-term investor at this moment. While there are some positive indicators like insider buying and a strong dividend yield, the company's financial performance has significantly declined, and the stock's short-term technical indicators and options sentiment suggest limited upside potential. The lack of strong proprietary trading signals further supports a cautious approach.
The MACD is positive and expanding, indicating bullish momentum, but the RSI is neutral at 64.482, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in price movement. Key resistance levels are at $29.495 and $30.578, with support at $25.988 and $24.905. The stock closed at $29.6, near its resistance level, limiting immediate upside potential.
Insiders have been buying shares, with a 159.06% increase in insider buying over the last month. The CFO's recent purchase at $27.95 reflects confidence in the company. The stock offers a 5.3% dividend yield, which is attractive for income-seeking investors.
The company's financial performance in Q1 2026 shows a significant decline in net income (-69.47% YoY) and EPS (-68.27% YoY). Analysts have lowered price targets significantly, citing increased execution risks and deceleration in growth. Options data indicates bearish sentiment, and the stock's trend suggests a potential decline in the next month.
In Q1 2026, revenue increased by 5.40% YoY to $2.5 billion, but net income dropped by 69.47% YoY to $20.4 million. EPS also fell by 68.27% YoY to $0.33, and gross margin declined by 5.66% to 29.84%. These figures indicate declining profitability despite revenue growth.
Analysts have lowered their price targets significantly, with Barrington reducing it to $38, Baird to $40, and Canaccord to $55. All firms maintain positive ratings (Outperform/Buy), but they highlight execution risks and deceleration in growth as concerns.
